Azienda Ospedaliera Ospedale Di Circolo E Fondazione Macchi, U.O.C Ematologia
Welcome,         Profile    Billing    Logout  
 9 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Merli, Michele
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
NCT04646395: Study of Acalabrutinib and Tafasitamab in MZL Patients

Active, not recruiting
2
26
Europe
Tafasitamab, MOR00208, Acalabrutinib, Calquence
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
09/27
03/28
PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
N/A
350
Europe
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
12/25
12/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
FIL_FollVax22, NCT06070961: Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

Recruiting
N/A
56
Europe
Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus, Humoral immunity vs Varicella Zoster Virus, Diphtheria toxin-binding IgG, Tetanus toxoid-binding IgG, T-cell populations and markers characterization
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
05/27
05/27
Marino, Dario
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
LH_BIO, NCT06822855: Changing Paragidms in the Prognostic Assessment of Hodgkin Lymphoma

Recruiting
N/A
755
Europe
Azienda Unità Sanitaria Locale Reggio Emilia
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
12/26
12/26
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
12/27
12/27
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Merli, Michele
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
NCT04646395: Study of Acalabrutinib and Tafasitamab in MZL Patients

Active, not recruiting
2
26
Europe
Tafasitamab, MOR00208, Acalabrutinib, Calquence
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
09/27
03/28
PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
N/A
350
Europe
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
12/25
12/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
FIL_FollVax22, NCT06070961: Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

Recruiting
N/A
56
Europe
Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus, Humoral immunity vs Varicella Zoster Virus, Diphtheria toxin-binding IgG, Tetanus toxoid-binding IgG, T-cell populations and markers characterization
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
05/27
05/27
Marino, Dario
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
LH_BIO, NCT06822855: Changing Paragidms in the Prognostic Assessment of Hodgkin Lymphoma

Recruiting
N/A
755
Europe
Azienda Unità Sanitaria Locale Reggio Emilia
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
12/26
12/26
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
12/27
12/27
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38

Download Options